baxdrostat (CIN-107) / AstraZeneca 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


123»
  • ||||||||||  zilebesiran (ALN-AGT) / Alnylam, Roche, Tryvio (aprocitentan) / J&J, baxdrostat (CIN-107) / AstraZeneca
    Review, Journal:  Novel pharmacologic approaches in resistant hypertension. (Pubmed Central) -  Dec 11, 2024   
    Recently, valsartan/sacubitrol and flozins have been increasingly used in resistant hypertension, which have been introduced for the treatment of diseases other than hypertension but can be a supplement to previously used drugs in resistant hypertension...The results to date allow for the consideration of aprocitentan (a drug that inhibits endothelin receptors) or baxdrostat or another new aldosterone synthesis inhibitor in the treatment of resistant hypertension that does not respond to 4 drugs, including spironolactone. Further studies are needed to confirm the efficacy and safety of these new drugs in the treatment of resistant hypertension.
  • ||||||||||  Journal:  Diagnosis and management of resistant hypertension. (Pubmed Central) -  Oct 28, 2024   
    Alternatives to spironolactone include amiloride, doxazosin, eplerenone, clonidine and beta-blockers, as well as any other antihypertensive drugs not already in use. New approaches under research are selective non-steroidal mineralocorticoid receptor antagonists such as finerenone, esaxerenone and ocedurenone, selective aldosterone synthase inhibitors such as baxdrostat, and dual endothelin antagonist aprocitentan.
  • ||||||||||  baxdrostat (CIN-107) / AstraZeneca
    Trial completion date, Trial primary completion date:  Bax24: A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension (clinicaltrials.gov) -  Oct 23, 2024   
    P3,  N=212, Recruiting, 
    New approaches under research are selective non-steroidal mineralocorticoid receptor antagonists such as finerenone, esaxerenone and ocedurenone, selective aldosterone synthase inhibitors such as baxdrostat, and dual endothelin antagonist aprocitentan. Trial completion date: Apr 2025 --> Sep 2025 | Trial primary completion date: Apr 2025 --> Sep 2025
  • ||||||||||  baxdrostat (CIN-107) / AstraZeneca
    The Persistent Challenge of Resistant Hypertension in CKD () -  Oct 12, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_5353;    
    Baxdrostat (an aldosterone synthase inhibitor) also garners high interest from specialists to treat uncontrolled hypertension...Conclusion. New pipeline products for hypertension, especially those tested in the CKD patient population, will offer nephrologists and cardiologists alternative treatment options to more effectively address one of the most challenging conditions that they face..
  • ||||||||||  baxdrostat (CIN-107) / AstraZeneca
    Effect of Baxdrostat on Albuminuria in Treatment-Resistant Hypertension (Exhibit Hall, Convention Center) -  Sep 23, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_3840;    
    P3
    Relatively few BrigHTN participants had CKD, and any amount of albuminuria was allowed. The phase 3 Arctic trial (NCT06268873) of patients with CKD and hypertension will compare baxdrostat/dapagliflozin to placebo/dapagliflozin both on top of maximally tolerated ACE inhibitors or angiotensin receptor blockers to assess the primary endpoint of change in eGFR over time.
  • ||||||||||  baxdrostat (CIN-107) / AstraZeneca
    Journal:  Can baxdrostat revamp resistant hypertension status in India? (Pubmed Central) -  Sep 9, 2024   
    The phase 3 Arctic trial (NCT06268873) of patients with CKD and hypertension will compare baxdrostat/dapagliflozin to placebo/dapagliflozin both on top of maximally tolerated ACE inhibitors or angiotensin receptor blockers to assess the primary endpoint of change in eGFR over time. No abstract available
  • ||||||||||  Tryvio (aprocitentan) / J&J, baxdrostat (CIN-107) / AstraZeneca
    Review, Journal:  The Global Burden of Resistant Hypertension and Potential Treatment Options. (Pubmed Central) -  Jul 10, 2024   
    However, achieving optimal BP control remains challenging in this setting. This review aims to provide an overview of RH, including its epidemiology, pathophysiology, diagnostic work-up, as well as the latest therapeutic developments.
  • ||||||||||  Kerendia (finerenone) / Bayer, aprocitentan (ACT-132577) / J&J, baxdrostat (CIN-107) / AstraZeneca
    Review, Journal:  Taming Resistant Hypertension - the promise of novel pharmacologic approaches and renal denervation. (Pubmed Central) -  Jan 15, 2024   
    Furthermore, the evidence base for consideration of catheter-based renal denervation as a safe and effective adjunct therapeutic approach across the clinical spectrum of hypertension has been further substantiated. This narrative review will summarise the recently published evidence on novel antihypertensive agents and renal denervation in the context of resistant hypertension.
  • ||||||||||  firibastat (QGC-001) / Quantum Genomics, Biolab Pharma, Orient Europharma, aprocitentan (ACT-132577) / J&J, baxdrostat (CIN-107) / AstraZeneca
    Review, Journal:  New trials in resistant hypertension: mixed blessing stories. (Pubmed Central) -  Jan 8, 2024   
    In conclusion, managing RH remains challenging, and new compounds like firibastat, aprocitentan and baxdrostat have shown varied effectiveness. Further research is needed to improve our understanding and treatment of this condition.
  • ||||||||||  baxdrostat (CIN-107) / AstraZeneca
    Review, Journal:  Revising the roles of aldosterone in vascular physiology and pathophysiology: from electocortin to baxdrostat. (Pubmed Central) -  Dec 17, 2023   
    The purpose of this review is to highlight recent advances in our understanding the biology of aldosterone as it relates to the pathophysiology and the management of vascular disease-especially related to hypertension. The review focuses on three key areas: 1) advances in our understanding of the cellular mechanisms by which aldosterone mediates its cellular effects, 2) identification of the hidden epidemic of aldosteronism as a mediator of hypertension and 3) appreciating new therapeutic advances in the clinical pharmacology of aldosterone inhibition in cardiovascular and renal disease.
  • ||||||||||  aprocitentan (ACT-132577) / J&J, baxdrostat (CIN-107) / AstraZeneca
    Journal:  Hypertension in chronic kidney disease - treatment standard 2023. (Pubmed Central) -  Dec 4, 2023   
    Larger and longer term clinical trials are needed to demonstrate the safety and efficacy of these novel therapies in the future. In this article, we review the current standards of treatment and discuss novel developments in pathophysiology, diagnosis, outcome prediction and management of hypertension in patients with CKD.
  • ||||||||||  baxdrostat (CIN-107) / AstraZeneca
    P2 data, Review, Journal:  Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension. (Pubmed Central) -  Nov 27, 2023   
    Future research endeavors will play a pivotal role in unveiling the effectiveness and safety profile of this novel medication. Thus, positioning baxdrostat as a valuable addition to the armamentarium of antihypertensive agents, especially for patients with complex, multifactorial hypertensive conditions.
  • ||||||||||  baxdrostat (CIN-107) / AstraZeneca
    Trial completion:  Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124 (clinicaltrials.gov) -  Nov 18, 2023   
    P2,  N=175, Completed, 
    Thus, positioning baxdrostat as a valuable addition to the armamentarium of antihypertensive agents, especially for patients with complex, multifactorial hypertensive conditions. Active, not recruiting --> Completed
  • ||||||||||  baxdrostat (CIN-107) / AstraZeneca
    Journal:  Baxdrostat: An Aldosterone Synthase Inhibitor for the Treatment of Systemic Hypertension. (Pubmed Central) -  Aug 7, 2023   
    A phase 2 trial, BrigHTN, showed promising results in demonstrating the efficacy of baxdrostat, where The HALO (efficacy and safety of baxdrostat in patients with uncontrolled hypertension) trial did not demonstrate any blood pressure-lowering benefit of baxdrostat when compared with the placebo. Several additional studies are now underway to evaluate the effectiveness of baxdrostat as an anti-hypertensive agent.
  • ||||||||||  baxdrostat (CIN-107) / AstraZeneca
    Enrollment closed, Trial primary completion date:  spark-PA: A Study of CIN-107 in Adults With Primary Aldosteronism (clinicaltrials.gov) -  Jul 3, 2023   
    P2,  N=15, Active, not recruiting, 
    Several additional studies are now underway to evaluate the effectiveness of baxdrostat as an anti-hypertensive agent. Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2023 --> Oct 2024
  • ||||||||||  baxdrostat (CIN-107) / AstraZeneca
    Journal:  Baxdrostat for Treatment-Resistant Hypertension. Reply. (Pubmed Central) -  May 14, 2023   
    Trial completion date: Aug 2024 --> Nov 2023 | Trial primary completion date: Aug 2024 --> Nov 2023 No abstract available